NCT04532710View on ClinicalTrials.gov

Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

May 27, 2021

Study Completion Date

May 27, 2021

Conditions
Allergic ConjunctivitisAllergic Rhinitis
Interventions
DRUG

Eye Drops, Solution in Single-Dose Container

Application of eye drops

Trial Locations (1)

1140

Vienna Challenge Chamber, Vienna

Sponsors
All Listed Sponsors
lead

Marinomed Biotech AG

INDUSTRY

NCT04532710 - Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis | Biotech Hunter | Biotech Hunter